MarginsXMarginsX
Home › Markets › Health Care › ASMB

Assembly Biosciences Inc. (ASMB)

ASMB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$21.29
+0.80% on the day
Market cap
$436.0M
Small cap
Revenue · 2025
$72.3M
+153.5% on 2024
Net income · 2025
-$6.1M
-8.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1426800/000119312526115992/0001193125-26-115992-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerASMB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2010
SEC CIK0001426800
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$72.3M
Net income-$6.1M
Operating income-$12.1M
Net margin-8.5%
Operating margin-16.8%
Revenue growth+153.5%
Cash$58.5M
Total assets$257.6M
P/E (computed)Net income was not positive
P/S (computed)6.0×

Warning signs

Cash runway
8.6 months
$29.1M cash at September 30, 2026
Share count, 1 year
+29.5%
2025-11-07 to 2026-11-06 · +274.0% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$15K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$29.1M cash; operating cash flow -$10.1M a quarter.Report 2026-09-30
Shares outstanding20,477,244 (2026-11-06); 15,817,140 a year earlier; 65,709,112 three years earlier. 3y figure adjusted for splits (1-for-12 overall).Cover page 2026-11-06
Reverse splits, 3 years1; latest 1-for-12 on 2024-02-12Source 2024-02-12
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedownsLatest 2026-05-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Jose, California, United StatesPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $15K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$3.0M-$20.3M-$17.2M$29.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
$13.4M-$3.9M-$15.5M$32.3MNo debt tagsNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
$8.2M-$9.1M-$22.1M$31.1MNo debt tagsNeeds four quarters10-Q 2026-05-07
Q4 2025
2025-12-31
Not filed$22.1M$14.2M$58.5MNo debt tags$72.3M10-K 2026-03-19
Q3 2025
2025-09-30
$10.8M-$9.2M-$15.1M$22.5MNo debt tags$37.2M10-Q 2026-11-12
Q2 2025
2025-06-30
$9.6M-$10.2M-$16.8M$24.0MNo debt tags$33.2M10-Q 2026-08-13
Q1 2025
2025-03-31
$9.4M-$8.8M-$23.4M$23.4MNo debt tags$32.2M10-Q 2026-05-07
Q4 2024
2024-12-31
$7.4M-$10.3M-$407K$38.3MNo debt tags$28.5M10-K 2025-03-20

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-26
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 904 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.4%
1 month+3.8%
3 months-29.5%
Year to date-37.9%
1 year-40.5%
From 52-week high-45.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BLSMBlossomHill Therapeutics Inc.$13.65-2.64%$433.9M
EOLSEvolus Inc.$6.63-4.74%$438.8M
CTMXCytomX Therapeutics Inc.$1.99-2.70%$432.7M
ARVNArvinas Inc.$6.77-0.73%$443.3M
AVTXAvalo Therapeutics Inc.$7.37-5.03%$426.2M
MPLTMapLight Therapeutics Inc.$6.90-4.83%$446.9M
DMACDiaMedica Therapeutics Inc.$8.33-5.23%$449.5M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier